BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models

DNA damaging agents cause rapid shrinkage of tumors and form the basis of chemotherapy for sarcomas despite significant toxicities. Drugs having superior efficacy and wider therapeutic windows are needed to improve patient outcomes. We used cell proliferation and apoptosis assays in sarcoma cell lin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Ambati, Srikanth R., Shieh, Jae-Hung, Pera, Benet, Lopes, Eloisi Caldas, Chaudhry, Anisha, Wong, Elissa W.P., Saxena, Ashish, Su, Tsann-Long, Moore, Malcolm A.S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5190008/
https://ncbi.nlm.nih.gov/pubmed/27248664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9657
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi